Annovis Bio (NYSE: ANVS) announced it has regained compliance with NYSE continued listing standards. The NYSE had notified the company on March 26, 2025 that its average global market cap and stockholders' equity were each below $50 million.
After NYSE accepted an 18‑month cure plan on June 19, 2025, Annovis executed corrective actions that raised both metrics above required thresholds within 12 months. NYSE has confirmed full compliance, and ANVS shares will remain listed as the company focuses on pivotal Phase 3 Alzheimer’s data and regulatory submissions.
Loading...
Loading translation...
Positive
Full NYSE continued listing compliance regained for ANVS
Market capitalization and stockholders' equity restored above $50 million thresholds
Compliance achieved in 12 months versus 18‑month cure period
NYSE listing and trading of ANVS common stock continues
Company able to refocus on pivotal Phase 3 AD milestones
Negative
Previous NYSE non‑compliance due to market cap below $50 million
Stockholders' equity also fell below $50 million triggering NYSE notice
News Market Reaction – ANVS
-7.62%
11 alerts
-7.62%News Effect
-12.6%Trough in 7 hr 47 min
-$7MValuation Impact
$90.61MMarket Cap
0.9xRel. Volume
On the day this news was published, ANVS declined 7.62%, reflecting a notable negative market reaction.
Argus tracked a trough of -12.6% from its starting point during tracking.
Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
This price movement removed approximately $7M from the company's valuation, bringing the market cap to $90.61M at that time.
The stock moved -7.6% in the session following this news. A negative reaction despite the compliance...
Analysis
The stock moved -7.6% in the session following this news. A negative reaction despite the compliance news would fit a pattern where ANVS has often traded lower around otherwise constructive updates. The company regained NYSE standards by lifting market cap and equity above the $50M thresholds within 12 months, but investors also face recent dilution, net losses, and prior going‑concern language. With shares trading below the 200‑day MA and volume well above the 20‑day average, moves could be amplified as traders reassess risk and capital needs.
Key Figures
Market cap threshold:$50 millionEquity threshold:$50 millionCompliance review window:30-trading-day period+4 more
7 metrics
Market cap threshold$50 millionMinimum average global market capitalization under NYSE Section 802.01B
Equity threshold$50 millionMinimum stockholders' equity required under NYSE Section 802.01B
Compliance review window30-trading-day periodPeriod over which average global market cap was measured
Cure period18-month cure periodTime allowed by NYSE from March 26, 2025 notice
Compliance timeframe12 monthsTime ANVS took to regain full NYSE compliance
Development stagePhase 3Clinical-stage status of buntanetap program
Pivotal AD studyPhase 3Topline data readout expected from pivotal Alzheimer’s study
Published Phase 2/3 AD trial showing dose-dependent cognitive improvements.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent ANVS news, including positive clinical and presentation updates, has often been followed by negative price reactions, while capital-raising and heavier-spending disclosures have aligned with share price declines.
Recent Company History
Over the past two months, ANVS has balanced clinical progress with significant financing and liquidity disclosures. A Phase 2/3 AD data publication on Apr 28 and a CEO conference presentation on May 7 highlighted buntanetap’s potential but were followed by share price declines. Subsequent earnings on May 15 and multiple equity offerings on Apr 9 and May 19–20 emphasized higher R&D spend, net losses, and dilution, also aligning with negative price moves. Today’s NYSE compliance news contrasts with that more pressured backdrop.
Key Terms
phase 3, oral therapy, neurodegenerative diseases, stockholders' equity, +4 more
8 terms
phase 3medical
"a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
oral therapymedical
"developing the investigational oral therapy, buntanetap, for neurodegenerative diseases"
A medicine or treatment taken by mouth, usually as a pill, capsule, or liquid, rather than injected or applied to the skin. For investors, oral therapies often mean easier distribution, lower administration costs and better patient convenience, which can boost adoption and sales compared with treatments that require clinic visits or specialized delivery, much like a product that’s easy to use at home tends to sell more than one that needs expert setup.
neurodegenerative diseasesmedical
"for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD)"
Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.
stockholders' equityfinancial
"while its stockholders' equity was also below $50 million"
Stockholders' equity is the portion of a company's assets that belongs to its owners after all debts and obligations are paid; think of it as the value left for shareholders if the company sold everything and paid off what it owes. Investors watch it because it shows the company's net worth, indicates how much of growth is funded by owners versus debt, and helps assess financial health and the potential for future dividends or stock value increases — like the equity in a house after the mortgage is settled.
continued listing standardsregulatory
"regained compliance with the New York Stock Exchange (NYSE) continued listing standards"
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.
topline data readouttechnical
"with topline data readout from the pivotal Phase 3 AD study"
A topline data readout is the initial summary of a clinical trial’s most important results, showing whether the study met its main goals. Like a headline score after a sports game, it gives investors a quick sense of success or failure that can shift a company’s outlook, affect future funding, and move the stock while more detailed analyses and regulatory reviews follow.
regulatory submissionsregulatory
"Phase 3 AD study and the regulatory submissions on the horizon"
Regulatory submissions are formal packages of data, documents and plans companies send to government agencies to get approval or permission for a product, service, or change—common in areas like drugs, medical devices, and securities filings. Investors care because these submissions determine whether a product can be sold, a trial can proceed, or a business action can occur; think of them as permit applications whose approval or rejection can significantly change a company's revenues and risk profile.
market capitalizationfinancial
"average global market capitalization had fallen below $50 million"
Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards.
On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equity was also below $50 million. On June 19, 2025, the NYSE accepted the Company's plan to regain compliance and granted an 18-month cure period from the date of the original notice.
To address it, Annovis executed a series of corrective actions to restore its market capitalization and stockholders' equity above the required thresholds and provided the NYSE with quarterly progress updates as required under the plan. Following these measures, the NYSE has confirmed that Annovis has regained full compliance with all applicable continued listing requirements. The Company's common stock will continue to be listed and traded on the NYSE under the ticker symbol "ANVS."
"We are pleased to have regained full NYSE compliance in just 12 months, well ahead of the 18-month deadline, and we thank the NYSE for their engagement throughout this process," said Alexander Morin, Ph.D., Director, Strategic Communications. "With this matter behind us, our attention remains firmly on advancing our clinical programs toward key milestones, with topline data readout from the pivotal Phase 3 AD study and the regulatory submissions on the horizon."
About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com
Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com
FAQ
What did Annovis Bio (NYSE: ANVS) announce on May 26, 2026 about NYSE compliance?
Annovis Bio reported it has regained full compliance with NYSE continued listing standards. According to Annovis, NYSE confirmed that ANVS now meets all required thresholds, allowing its common stock to remain listed and traded under the existing ticker.
Why was Annovis Bio (ANVS) previously out of compliance with NYSE listing rules?
Annovis Bio was deemed non‑compliant because its average global market capitalization fell below $50 million and stockholders' equity was also under $50 million. According to Annovis, this triggered a March 26, 2025 NYSE notice under Section 802.01B.
How did Annovis Bio regain NYSE listing compliance for ANVS shares?
Annovis Bio implemented corrective actions to raise its market capitalization and stockholders' equity above NYSE thresholds. According to Annovis, it executed this NYSE‑accepted cure plan with required quarterly updates, leading to confirmation of full compliance within 12 months.
How long did Annovis Bio take to restore NYSE compliance compared with the cure period?
Annovis Bio regained NYSE compliance in about 12 months, earlier than the 18‑month cure period granted. According to Annovis, NYSE accepted its plan on June 19, 2025, starting the cure window from the original March 26, 2025 notice date.
What does regained NYSE compliance mean for Annovis Bio (ANVS) shareholders?
Regained NYSE compliance means ANVS common stock will continue trading on the NYSE under the same ticker. According to Annovis, resolving this issue lets management focus on advancing clinical programs and upcoming Phase 3 Alzheimer’s data and regulatory submissions.
What are Annovis Bio's next milestones after regaining NYSE compliance?
After regaining NYSE compliance, Annovis plans to focus on its clinical pipeline. According to Annovis, key upcoming milestones include topline data from the pivotal Phase 3 Alzheimer’s disease study of buntanetap and related regulatory submissions on the horizon.
